Hepatitis Clinical Trials

347 recruitingLast updated: June 17, 2026

There are 347 actively recruiting hepatitis clinical trials across 72 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include Guangzhou, Guangdong, China, New York, New York, United States, Baltimore, Maryland, United States. Updated daily from ClinicalTrials.gov.


Hepatitis Trials at a Glance

347 actively recruiting trials for hepatitis are listed on ClinicalTrialsFinder across 6 cities in 72 countries. The largest study group is Phase 2 with 66 trials, with the heaviest enrollment activity in Guangzhou, New York, and Baltimore. Lead sponsors running hepatitis studies include Third Affiliated Hospital, Sun Yat-Sen University, Ausper Biopharma Co., Ltd., and Hospices Civils de Lyon.

Treatments under study

About Hepatitis Clinical Trials

Looking for clinical trials for Hepatitis? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hepatitis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hepatitis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 347 trials

Recruiting
Phase 2

Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH

MASH - Metabolic Dysfunction-Associated Steatohepatitis
Madrigal Pharmaceuticals, Inc.120 enrolled17 locationsNCT07335601
Recruiting
Phase 2

Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial

Alcohol Associated Hepatitis
Samer Gawrieh216 enrolled6 locationsNCT07060638
Recruiting
Not Applicable

Host-Diet-Gut Interaction Post Vegan Diet in Pediatric Autoimmune Hepatitis.

Autoimmune Hepatitis
Institute of Liver and Biliary Sciences, India40 enrolled1 locationNCT07118657
Recruiting
Phase 1Phase 2

TherVacB - A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate

Chronic Hepatitis B
Michael Hoelscher81 enrolled6 locationsNCT06513286
Recruiting
Phase 1Phase 2

Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus

Chronic Hepatitis Delta
Gilead Sciences200 enrolled19 locationsNCT07096193
Recruiting
Phase 3

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

Metabolic dysfunction-associated steatohepatitis (MASH)Liver Fibrosis
Boehringer Ingelheim1,800 enrolled526 locationsNCT06632444
Recruiting
Phase 3

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

Metabolic Dysfunction-Associated Steatohepatitis
Boehringer Ingelheim1,590 enrolled447 locationsNCT06632457
Recruiting
Phase 3

A Phase III Study to Evaluate the Efficacy and Safety of Libevitug in Participants With Chronic HDV Infection (D-clear Study)

Chronic Hepatitis D Infection
Huahui Health160 enrolled1 locationNCT07499544
Recruiting

Feasibility and Acceptability of HCV Treatment in Pregnancy

Pregnancy ComplicationsHepatitis C
Washington University School of Medicine50 enrolled2 locationsNCT06367465
Recruiting
Phase 1Phase 2

Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV

Hepatitis C
National Institute of Allergy and Infectious Diseases (NIAID)30 enrolled10 locationsNCT07040319
Recruiting
Not Applicable

Alcohol Treatment Outcomes Following Early vs. Standard Liver Transplant for SAH

Alcoholic HepatitisAlcohol Use Disorder
Johns Hopkins University200 enrolled1 locationNCT03845205
Recruiting
Phase 3

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

MASH - Metabolic Dysfunction-Associated SteatohepatitisNASH - Nonalcoholic Steatohepatitis
Akero Therapeutics, Inc2,150 enrolled322 locationsNCT06528314
Recruiting
Phase 2

A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)

Metabolic Dysfunction-Associated Steatohepatitis
Eccogene160 enrolled58 locationsNCT07288138
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
89bio, Inc.762 enrolled303 locationsNCT06419374
Recruiting

Screening and Follow-up in Patients With HIV Infection Combined With Metabolic Associated Fatty Liver Disease

FibrosisNonalcoholic SteatohepatitisNonalcoholic Fatty Liver Disease+1 more
Peking Union Medical College Hospital2,000 enrolled1 locationNCT05330923
Recruiting
Phase 3

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
89bio, Inc.1,350 enrolled349 locationsNCT06318169
Recruiting

Diagnostic Value of the Liver Inflammation Index for MASH in Patients With T2DM and MAFLD

Type 2 Diabetes Mellitus (T2DM)MASH - Metabolic Dysfunction-Associated SteatohepatitisMetabolic Dysfunction-associated Fatty Liver Disease
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School10,000 enrolled22 locationsNCT07632677
Recruiting
Phase 2

A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus

MASH - Metabolic Dysfunction-Associated SteatohepatitisT2DM (Type 2 Diabetes Mellitus)
Shanghai Jiao Tong University School of Medicine300 enrolled17 locationsNCT07303803
Recruiting
Phase 2

Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

CirrhosisCirrhosis, LiverCirrhosis Due to Hepatitis B+5 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)256 enrolled13 locationsNCT05832229
Recruiting
Not Applicable

Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis

NASH - Nonalcoholic Steatohepatitis
University of Minnesota48 enrolled4 locationsNCT03587831